COR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2026Q2

FY2026Q3

86.03B

+5.57%

4.072

+9.18%

79.95B

+5.95%

4.921

+11.34%

85.42B

+5.9%

4.348

+8.71%

Estimates Revision

The market is revising Downward the revenue expectations for Cencora, Inc. (COR) for FY2026, with the revenue forecasts being adjusted by -0.41% over the past three months. During the same period, the stock price has changed by 20.80%.

Revenue Estimates for FY2026

Revise Downward

-0.41%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+1.19%

In Past 3 Month

Stock Price

Go Up

+20.80%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is 393.78 USD with a low forecast of 361.00 USD and a high forecast of 417.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 350.320

Low

361.00

Averages

393.78

High

417.00

Current: 350.320

Low

361.00

Averages

393.78

High

417.00

Barclays

Overweight

initiated

$400

2025-12-08

Reason

Barclays

Price Target

$400

2025-12-08

initiated

Overweight

Reason

Barclays initiated coverage of Cencora with an Overweight rating and $400 price target. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.

Wells Fargo

Overweight

maintain

$354 -> $405

2025-11-11

Reason

Wells Fargo

Price Target

$354 -> $405

2025-11-11

maintain

Overweight

Reason

Wells Fargo raised the firm's price target on Cencora to $405 from $354 and keeps an Overweight rating on the shares. The firm says the company reported fairly strong Q4 results and introduced attractive FY26 guidance. Core growth in U.S. Healthcare remains outstanding and absent material deceleration would seem to suggest potential for additional positive estimate revisions, Wells adds.

JPMorgan

NULL -> Overweight

maintain

$344 -> $417

2025-11-11

Reason

JPMorgan

Price Target

$344 -> $417

2025-11-11

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Cencora to $417 from $344 and keeps an Overweight rating on the shares. The firm updated the company's model.

TD Cowen

Buy

maintain

$350 -> $400

2025-11-10

Reason

TD Cowen

Price Target

$350 -> $400

2025-11-10

maintain

Buy

Reason

TD Cowen raised the firm's price target on Cencora to $400 from $350 and keeps a Buy rating on the shares. The firm said they remain confident in the shares following F4Q25 and the introduction of its FY26 guidance where they continue to see upside.

UBS

Buy

maintain

$380 -> $415

2025-11-07

Reason

UBS

Price Target

$380 -> $415

2025-11-07

maintain

Buy

Reason

UBS raised the firm's price target on Cencora to $415 from $380 and keeps a Buy rating on the shares. The initial guidance for the U.S. Healthcare Solutions segment EBIT is doable, if not conservative, the analyst tells investors in a research note.

Deutsche Bank

NULL -> Buy

maintain

$322 -> $371

2025-11-07

Reason

Deutsche Bank

Price Target

$322 -> $371

2025-11-07

maintain

NULL -> Buy

Reason

Deutsche Bank raised the firm's price target on Cencora to $371 from $322 and keeps a Buy rating on the shares.

Valuation Metrics

The current forward P/E ratio for Cencora Inc (COR.N) is 19.58, compared to its 5-year average forward P/E of 14.50. For a more detailed relative valuation and DCF analysis to assess Cencora Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

14.50

Current PE

19.58

Overvalued PE

16.76

Undervalued PE

12.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

10.62

Current EV/EBITDA

14.12

Overvalued EV/EBITDA

12.32

Undervalued EV/EBITDA

8.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.14

Current PS

0.20

Overvalued PS

0.16

Undervalued PS

0.11

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 2472.49% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

COR News & Events

Events Timeline

No data

News

8.5

12-15Newsfilter

PinnedCencora Acquires OneOncology for $7.4 Billion, Enhancing Growth Strategy

8.5

12-15NASDAQ.COM

PinnedCencora Set to Purchase Majority Stake in OneOncology for Approximately $5 Billion

4.5

12-12NASDAQ.COM

ETF Inflow Alert: IWP, NET, HLT, COR

People Also Watch

Frequently Asked Questions

What is Cencora Inc (COR) stock price today?

The current price of COR is 350.32 USD — it has increased 1.25 % in the last trading day.

What is Cencora Inc (COR)'s business?

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

What is the price predicton of COR Stock?

What is Cencora Inc (COR)'s revenue for the last quarter?

Cencora Inc revenue for the last quarter amounts to 83.73B USD, increased 5.92 % YoY.

What is Cencora Inc (COR)'s earnings per share (EPS) for the last quarter?

Cencora Inc. EPS for the last quarter amounts to -1.75 USD, decreased -8850.00 % YoY.

What changes have occurred in the market's expectations for Cencora Inc (COR)'s fundamentals?

How many employees does Cencora Inc (COR). have?

Cencora Inc (COR) has 51000 emplpoyees as of December 16 2025.

What is Cencora Inc (COR) market cap?

Today COR has the market capitalization of 67.12B USD.